Home/Pipeline/SKB378

SKB378

Asthma

Phase 1Active

Key Facts

Indication

Asthma

Phase

Phase 1

Status

Active

Company

Klus Pharma

About Klus Pharma

KLUS Pharma is a U.S.-based biotech subsidiary of China's Kelun-Biotech, leveraging its parent company's integrated R&D and manufacturing platforms to advance a diverse pipeline of oncology and non-oncology biologics. The company has built a robust pipeline with multiple clinical-stage assets, most notably in the competitive ADC space, including TROP2 and HER2-targeting candidates. Its strategy combines internal development with strategic partnerships, such as the recent collaboration with Crescent Biopharma, to maximize the global value of its pipeline. KLUS operates as a key bridge for Kelun-Biotech's ambitions in the U.S. and international markets.

View full company profile

Therapeutic Areas

Oncology Asthma Thromboembolic disorders Autoimmune Disease Cardiovascular Disease

Other Asthma Drugs

Drug	Company	Phase	Status
Technegas® for Asthma	Cyclomedica	Phase 2	Active
Asthma Candidate	Teva	Phase 3	Active
Montelukast Amorphous Form	Morepen Laboratories	Phase-2	Active
Chitinase Inhibitor	Lead Discovery Siena	Discovery	Active
RIG-101	RIGImmune	Pre-clinical	Active
Asthma Clinical Trials	American Health Research	Not Disclosed	Active
Advanced Asthma Products	Polpharma	Not Disclosed	Active
Solrikitug	Uniquity Bio	Phase 2	Active
Asthma Trial	Science 37	Phase 3	Completed/Highlighted
CAL-4	Calyxha Biotechnologies	Preclinical	Active
Digital Biomarker for Asthma	electronRx	Early Development	Active
Flutiform	KYORIN Pharmaceutical	Marketed	Active